Summary
The contents of interleukin (IL)-2 and basic fibroblast growth factor (bFGF) were measured in the brain (caudate nucleus, putamen, and cerebral cortex) from control and parkinsonian patients by highly sensitive enzyme-linked immunosorbent assay (ELISA). The concentrations of IL-2 in the brain were in the order of pg/mg protein, and the values were significantly higher in the caudate and putamen from parkinsonian patients than those from control patients. However, the levels of IL-2 in the cerebral cortex showed no significant difference between parkinsonian and control patients. In contrast to IL-2, the bFGF levels in the brain were high and in the order of ng/mg protein, and there was no significant difference in the caudate and putamen between parkinsonian and control patients. Although both IL-2 and bFGF may play important roles in dopaminergic neurons as neurotrophic factors, IL-2 but not bFGF may relate to the compensatory response in the nigrostriatal dopaminergic regions in parkinsonian brain during progress of neurodegeneration.
This is a preview of subscription content, log in via an institution to check access.
References
Bean AJ, Elde R, Cao YH, Oellig C, Tamminga C, Goldstein M, Pettersson RF, Hokfelt T (1991) Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human. Proc Natl Acad Sci USA 88: 10,237–10,241
Benveniste EN, Merrill JE (1986) Stimulation of oligodendroglial proloferation and maturation by interleukin-2. Nature 321: 610–613
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254
Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4,546–4,550
Chiueh CC, Burns RS, Markey SP, Jacobowitz DM, Kopin IJ (1985) Primate model of parkinsonism: selective lesion of nigrostriatal neurons by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 36: 213–228
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249–254
Ferrara N, Ousley F, Gospodarowicz D (1988) Bovine brain astrocytes express basic fibroblast growth factor, a neurotropic and angiogenic mitogen. Brain Res 462: 223–232
Freed WJ, Morihisa JM, Spoor E, Hoffer BJ, Olson L, Seiger A, Wyatt RJ (1981) Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature 292: 351–352
Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, Stebbins G, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt T, Cox C, Waxman M, Gauger L (1989) Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med 320: 337–341
Greenfield SA (1992) Cell death in Parkinson's disease. In: Tipton KF (ed) Essays in biochemistry, vol 27. Portlend Press, London, pp 103–118
Grothe C, Unsicker K (1989) Immunocytochemical localization of basic fibroblast growth factor in bovine adrenal gland, ovary, and pituitary. J Histochem Cytochem 37: 1,877–1,883
Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1,451–1,453
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Liang SM, Liang CM, Chiueh CC (1989) Visualization of interleukin-2-like molecules in MPP†lesioned rat brain. Biochem Biophys Res Commun 165: 1,312–1,318
Mogi M, Harada M, Kojima K, Kiuchi K, Nagatsu I, Nagatsu T (1987) Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase activity in vitro and tyrosine hydroxylase content. Neurosci Lett 80: 213–218
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994a) Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165: 208–210
Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994b) Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth fator-α are elevated in the brain from parkinsonian patients. Neurosci Lett 180: 147–150
Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T (1995) Brain β2-microglobulin levels are elevated in the striatum in Parkison's disease. J Neural Transm [P-D Sect] 9: 87–92
Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1,007–1,008
Morrison RS, Kornblum HI, Leslie FM, Bradshaw RA (1987) Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor. Science 238: 72–75
Otto D, Unsicker K (1990) Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J Neurosci 10: 1912–1921
Sternberg EM (1989) Monokines, lymphokines and the brain. In: Cruse JM, Lewis Jr RE (eds) The year in immunology 1988: immunoregulatory cytokines and cell growth, vol 5. Karger, Basel, pp 205–217
Snyder SH (1991) Parkinson's disease, fresh factors to consider. Nature 350: 195
Yoshida K, Gage FH (1991) Fibroblast growth factors stimulate nerve growth factor synthesis and secretion by astrocytes. Brain Res 538: 118–126
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mogi, M., Harada, M., Kondo, T. et al. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. J. Neural Transmission 103, 1077–1081 (1996). https://doi.org/10.1007/BF01291792
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01291792